PRESS INFORMATION

Olympus Launches First Three Applications of OLYSENSE™ CAD/AI Portfolio in EMEA

Hamburg, September 30, 2025 – Olympus Europa SE & Co. KG (Olympus) today announced the commercial launch of the first three applications within its OLYSENSE™ CAD/AI portfolio. Initially available in selected European countries, the cloud-based, integrated, and adaptable suite of seamlessly connected apps and solutions is designed to address clinical and operational performance and marks Olympus' first step towards creating its intelligent endoscopy ecosystem. The OLYSENSE CAD/AI portfolio allows healthcare professionals to harness the power of artificial intelligence (AI), with the aim of detecting and characterizing suspected tissues and lesions.

Healthcare is evolving. Gastroenterologists today face increasing challenges, like heightened workloads, administrative burdens, budget constraints, and staff shortages. At the same time, the need for endoscopic procedures is increasing in light of demographic trends and ubiquitous lower and upper gastrointestinal conditions. Efficient screening, early diagnosis, and appropriate treatment are vital for patient outcomes. Data-driven and AI-based solutions are designed to address these demands. That is why Olympus is introducing OLYSENSE to seamlessly integrate these advanced digital technologies with endoscopic devices.

"Since developing the world's first gastro-camera over 70 years ago, Olympus has been committed to addressing the evolving needs of both healthcare providers and patients in the field of endoscopy," says Miquel-Àngel García, Sr. Vice Pres. and General Manager of Endoscopy Solutions Ecosystem at Olympus. *"Launching an intelligent endoscopy ecosystem that connects software, hardware, and services across the whole endoscopy care pathway, is the next step on this journey."*

Intelligent support for clinicians

At launch, the **OLYSENSE CAD/AI** software application portfolio will include three separate cloud-based, AI-supported apps designed to assist healthcare professionals in the early diagnosis of lower and upper GI diseases during endoscopy procedures: CADDIE™, CADU™, and SMARTIBD™. These three advanced medical device software products received the CE approval for Europe under the Medical Device Regulations (MDR) last year and are now commercially available in the region.

CADDIE, a cloud-based AI for colonoscopy, assists gastroenterologists in the detection and characterization of suspected polyps and potential early signs of colorectal cancer. Trained on a robust dataset to identify potential colorectal lesions in colonoscopy video frames, it delivers instant image analysis on the endoscopy monitor–supporting endoscopists in making informed decisions in real time. With CADDIE, Olympus aims to positively impact the prevention and early detection of colorectal cancer by showing a 7.4% absolute increase in adenoma detection rate (ADR) compared to standard of care.[1]

A multi-center randomized controlled trial conducted across eight European hospitals demonstrated the technology's potential for hard-to-detect and high-risk polyps[2]: When CADDIE was utilized in said trial, endoscopists achieved a relative increase of 136% in detected large polyps and 93% in detected large adenomas. Additionally, they detected 2.3 times more sessile serrated lesions (SSL), the most common precancerous serrated polyps, and up to 57% more flat adenomas, relative to when they did not use the AI system during a procedure.

"Cloud-based and AI-powered endoscopy solutions are transforming clinical practice. By enabling real-time decision support and standardized assessments, they help clinicians diagnose earlier and more accurately, streamline workflows, and improve patient outcomes", comments Prof. Cesare Hassan, Gastroenterologist from the Humanitas University in Milan, Italy. *"Endoscopy on the cloud opens the door for continuous innovation and broader access to advanced care."*

Leveraging AI for diverse applications

While CADDIE contributes to the detection and characterization of colorectal polyps, the second AI-powered application CADU addresses another gastrointestinal condition known as Barrett's Esophagus. It highlights areas with the highest likelihood of dysplasia in endoscopy images, aiming to support healthcare professionals in accurate clinical decision-making. Finally, the third algorithm SMARTIBD assists in the analysis of Ulcerative Colitis in line with the MAYO scoring. The three applications underpin OLYSENSE CAD/AI's diverse capabilities within the endoscopy unit to contribute to improving patient outcomes across various disease states.

1 Data on file with Odin Medical Ltd., CADDIE AI Trial - NCT04325815.
[2] Data not yet peer reviewed/published. Data on file with Odin Medical Ltd, EAGLE Trial — NCT05730192

In the future, the ecosystem's applications and offerings will continue to evolve: complementing its AI-powered clinical solutions with seamless data connectivity across the GI unit and integration with hospital systems to drive clinical and operational efficiency as well as simplicity.

"The commercial launch of our OLYSENSE CAD/AI applications marks an exciting milestone, as we introduce the first component of our intelligent endoscopy ecosystem and provide our customers with an innovative, cloud-based solution that can help them advance their clinical performance," says Oliver Burghardt, VP Medical Endoscopy Group for Olympus EMEA.

Find out more about OLYSENSE by visiting our **website**, and joining us at UEG Week in Berlin from October 4th to 7th.

DISCLAIMER

* The contents of this press release are aimed at healthcare professionals only.
* This product may not be available in all regions. As with any medical device, careful consideration should be given to all applicable labeling, including potential risks and benefits associated with the product.
* Healthcare professionals mentioned in this press release have a business relationship with Olympus.
* All company names and product names mentioned are trademarks or registered trademarks of their respective companies. All trademarks and registered trademarks are the property of their respective owners.

About Olympus

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Olympus Europa, headquartered in Hamburg, Germany, serves the EMEA (Europe, Middle East, Africa) Region and employs 7,600 people in 29 countries. For more information, visit **www.olympus-europa.com** and follow our LinkedIn account: **linkedin.com/company/olympus-corp**.

For questions or additional information, please contact:

Matthias Gengenbach
Head of Corporate Communications EMEA
Olympus Europa SE & Co. KG
Tel.: +49 151 4236 9420
Email: **matthias.gengenbach@olympus-europa.com**
www.olympus-europa.com